Related Experiment Video

Updated: May 29, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

EphA2-dependent molecular targeting therapy for malignant tumors

Rong Biao-xue1, Cai Xi-guang, Yang Shuan-ying

  • 1Department of Respiratory Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi’an, Shaanxi, China.

Current Cancer Drug Targets
|September 22, 2011
PubMed

Insights

EphA2 receptor is overexpressed in cancers, promoting tumor growth and survival. Targeting EphA2 with antagonists may offer a novel strategy for developing effective anti-cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Understanding oncogenesis and drug resistance is crucial for developing targeted cancer therapies.
  • EphA2 receptor is frequently overexpressed in various human cancers.
  • EphA2 overexpression correlates with increased tumor invasion and reduced patient survival.

Purpose of the Study:

  • To review the role of EphA2 in cancer development (tumorigenesis).
  • To summarize the development of EphA2 receptor antagonists as potential anti-cancer agents.
  • To highlight the therapeutic potential of targeting EphA2 in solid tumors.

Main Methods:

  • Literature review of studies on EphA2 in cancer.
  • Analysis of EphA2 signaling pathways in tumorigenesis.
  • Overview of different classes of EphA2 receptor antagonists (e.g., tyrosine kinase inhibitors, antibodies, small molecules, peptides, siRNA, antibody-drug conjugates).

Main Results:

  • EphA2 plays a significant role in promoting cancer progression.
  • Various antagonists targeting EphA2 have been developed.
  • These antagonists show promise as novel anti-cancer therapeutics.

Conclusions:

  • EphA2 is a critical target for anti-cancer drug development.
  • Targeted therapies inhibiting EphA2 signaling hold potential for treating solid tumors.
  • Further research into EphA2 function can lead to more effective cancer treatments.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.